$EVOK
Evoke Pharma Inc

2019 Q2 Form 10-Q Financial Statement

#000156459019030433 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $920.0K $920.0K
YoY Change 0.0% 5.75%
% of Gross Profit
Research & Development $1.206M $1.389M
YoY Change -13.19% -31.17%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.124M $2.306M
YoY Change -7.91% -20.19%
Operating Profit -$2.124M -$2.306M
YoY Change -7.91%
Interest Expense $9.642K $2.903K
YoY Change 232.14% 74.15%
% of Operating Profit
Other Income/Expense, Net $9.642K $2.902K
YoY Change 232.25% -99.77%
Pretax Income -$2.110M -$2.300M
YoY Change -8.26% 41.1%
Income Tax
% Of Pretax Income
Net Earnings -$2.114M -$2.303M
YoY Change -8.21% 41.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14
Diluted Earnings Per Share -$90.71K -$0.14
COMMON SHARES
Basic Shares Outstanding 23.26M
Diluted Shares Outstanding 16.43M

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.440M $6.530M
YoY Change 13.94% -48.01%
Cash & Equivalents $7.440M $6.531M
Short-Term Investments
Other Short-Term Assets $11.55K $90.00K
YoY Change -87.17% -84.75%
Inventory
Prepaid Expenses $109.7K
Receivables
Other Receivables
Total Short-Term Assets $7.561M $6.630M
YoY Change 14.05% -49.54%
LONG-TERM ASSETS
Property, Plant & Equipment $70.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $69.80K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $7.561M $6.630M
Total Long-Term Assets $69.80K $0.00
Total Assets $7.631M $6.630M
YoY Change 15.1% -49.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $410.0K $440.0K
YoY Change -6.82% -60.71%
Accrued Expenses $880.0K $820.0K
YoY Change 7.32% 7.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.285M $1.270M
YoY Change 1.18% -32.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.285M $1.270M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.290M $1.270M
YoY Change 1.57% -80.13%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.346M $5.360M
YoY Change
Total Liabilities & Shareholders Equity $7.630M $6.630M
YoY Change 15.08% -49.62%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$2.114M -$2.303M
YoY Change -8.21% 41.65%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.630M -$1.760M
YoY Change -7.39% -15.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.040M 2.890M
YoY Change 74.39%
NET CHANGE
Cash From Operating Activities -1.630M -1.760M
Cash From Investing Activities
Cash From Financing Activities 5.040M 2.890M
Net Change In Cash 3.410M 1.130M
YoY Change 201.77% -154.07%
FREE CASH FLOW
Cash From Operating Activities -$1.630M -$1.760M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
001-36075
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2165749
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
393775
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
544643
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
208447886
dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
2123738
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
2306096
dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
dei City Area Code
CityAreaCode
(858)
dei Local Phone Number
LocalPhoneNumber
345-1494
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7440079
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5319004
CY2019Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
109739
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
329218
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2019Q2 us-gaap Assets Current
AssetsCurrent
7561369
CY2018Q4 us-gaap Assets Current
AssetsCurrent
5648222
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
69795
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2019Q2 us-gaap Assets
Assets
7631164
CY2018Q4 us-gaap Assets
Assets
5659773
CY2019Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
407517
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
476202
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
807706
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1158251
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
69795
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1285018
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1634453
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24113956
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17427533
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24113956
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17427533
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1205599
CY2018Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1388791
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1952481
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2774157
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
918139
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
917305
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2141152
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1949550
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14271
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4335
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433392
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2902
us-gaap Net Income Loss
NetIncomeLoss
-4079362
us-gaap Net Income Loss
NetIncomeLoss
-4285980
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16425468
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20371442
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15926253
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
378959
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
636432
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965266
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3075445
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
344841
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5039956
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3267885
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1982786
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
4389266
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
387429
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2886877
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
5360378
us-gaap Share Based Compensation
ShareBasedCompensation
723800
us-gaap Share Based Compensation
ShareBasedCompensation
781204
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-285496
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-167364
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-485247
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-808904
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3555313
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4579708
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5676388
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3431520
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5676388
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3431520
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2121075
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1148188
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7679267
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6531079
evok Reclassification Of Warrant Liability To Equity Due To Amendment Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToAmendmentOfWarrants
3267885
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2019Q2 evok Minimum Common Stock Closing Bid Price Per Share
MinimumCommonStockClosingBidPricePerShare
1.00
CY2019Q2 evok Initial Period To Regain Compliance
InitialPeriodToRegainCompliance
P180D
CY2019Q2 evok Number Of Minimum Consecutive Business Days
NumberOfMinimumConsecutiveBusinessDays
10
evok Closing Bid Price Description
ClosingBidPriceDescription
On May 15, 2019, the Company received a letter from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq listing rules, the Company has been provided an initial period of 180 calendar days, or until November 11, 2019, to regain compliance. The letter states that Nasdaq will provide written notification that the Company has achieved compliance with its rules if at any time before November 11, 2019, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq letter has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market.
CY2018Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
30165
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
37582
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5946432
evok Lease Commencement Date
LeaseCommencementDate
2017-01-01
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2019-12-31
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
36000
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
35000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
74000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
69000
evok Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.12
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
136000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
136000
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.75
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
2456999
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1842746
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.62
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
84000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
344841
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
387429
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D

Files In Submission

Name View Source Status
0001564590-19-030433-index-headers.html Edgar Link pending
0001564590-19-030433-index.html Edgar Link pending
0001564590-19-030433.txt Edgar Link pending
0001564590-19-030433-xbrl.zip Edgar Link pending
evok-10q_20190630.htm Edgar Link pending
evok-20190630.xml Edgar Link completed
evok-20190630.xsd Edgar Link pending
evok-20190630_cal.xml Edgar Link unprocessable
evok-20190630_def.xml Edgar Link unprocessable
evok-20190630_lab.xml Edgar Link unprocessable
evok-20190630_pre.xml Edgar Link unprocessable
evok-ex311_10.htm Edgar Link pending
evok-ex312_8.htm Edgar Link pending
evok-ex321_6.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending